AAV5 Delivery of CRISPR/Cas9 Mediates Genome Editing in the Lungs of Young Rhesus Monkeys

Genomics Genomics
Medicine Medicine
Technology Technology
Alex K. Shalek Alex K. Shalek
Andrew Navia Andrew Navia
Michelle Ramseier Michelle Ramseier

Liang et al.▾ Liang, S., Navia, A. W.,Ramseier, M.,Zhou, X., Martinez, M., Lee, C.,Zhou, C., Xie, J., Su, Q., Wang, D., Flotte, T. R., Anderson, D. G., Tarantal, A. F., Shalek, A. K., Gao, G., Xue, W.

Human Gene Therapy , Volume 35

October, 2024

Abstract

Genome editing has the potential to treat genetic diseases in a variety of tissues, including the lung. We have previously developed and validated a dual adeno-associated virus (AAV) CRISPR platform that supports effective editing in the airways of mice. To validate this delivery vehicle in a large animal model, we have shown that intratracheal instillation of CRISPR/Cas9 in AAV5 can edit a housekeeping gene or a disease-related gene in the lungs of young rhesus monkeys. We observed up to 8% editing of angiotensin-converting enzyme 2 (ACE2) in lung lobes after single-dose administration. Single-nuclear RNA sequencing revealed that AAV5 transduces multiple cell types in the caudal lung lobes, including alveolar cells, macrophages, fibroblasts, endothelial cells, and B cells. These results demonstrate that AAV5 is efficient in the delivery of CRISPR/Cas9 in the lung lobes of young rhesus monkeys.